This is a maintenance filing — no material change to the company's liquidity or capital structure. The extension of the revolver to April 2027 removes near-term refinancing risk at current lender. Monitor the Q3 2026 10-Q for any changes in drawn balances under these facilities and the company's overall leverage profile.
Price Chart
Executive Summary
Integrated BioPharma entered into an amendment with PNC Bank that extends its $4M revolving credit facility maturity by one year to April 2027 and replaced its matured $500K equipment line with a new $250K convertible equipment line of credit. This is a routine refinancing and extension of existing credit arrangements — no change in total committed capacity and no new cash infusion beyond equipment financing.
Key Financial Metrics
Key Facts
- Revolving line of credit extended to April 14, 2027, with aggregate principal up to $4,000,000 unchanged
- Prior $500,000 Convertible Equipment Line of Credit Note terminated (matured) and replaced with a new $250,000 Convertible Line of Credit Note for equipment/vehicle purchases
- New convertible ELOC bears interest at Daily 1M SOFR plus 250 bps prior to conversion, converting to 60-month amortizing term loan on the earlier of 12 months or borrower notice
- Amendment included $4,000 fee to PNC and $2,500 in legal cost reimbursement
- No new equity, no dilution — both facilities are secured debt from the same bank lender
Financial Impact
Routine extension of existing $4M revolver and replacement of a matured $500K equipment note with a new $250K equipment note. Net reduction in committed equipment facility capacity of $250K.
Risk Factors
- New $250K convertible ELOC is secured and bears floating-rate interest (SOFR +250bps), exposing the company to rising short-term rates
- Net reduction in equipment credit capacity from $500K to $250K could constrain capital spending if larger equipment needs arise
- The amendment added comprehensive sanctions/AML/anti-corruption covenants that create additional compliance obligations and potential default triggers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-022415 |
| Exhibit: ex_983423.htm | 0001437749-26-022415 |
| Document: inbp20260630_8k.htm | 0001437749-26-022415 |
| Document: 0001437749-26-022415-index-headers.html | 0001437749-26-022415 |
| Document: 0001437749-26-022415-index.html | 0001437749-26-022415 |
| Document: 0001437749-26-022415.txt | 0001437749-26-022415 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $0.1700 $0.1800 | ▼ −5.88% | ▼ −5.91% | $0.1700 (−0.00%) |
Aug 20, 2026 9w ago | 8-K | $0.1800 $0.1700 | ▼ −5.56% | ▼ −5.56% | $0.1700 (−5.56%) |
Jul 2, 2026 16w ago | 8-K | $0.1800 $0.1600 | ▼ −11.11% | ▼ −10.70% | $0.1700 (−5.56%) |
May 8, 2026 24w ago | 8-K | $0.2500 $0.1800 | ▲ +28.00% | ▲ +27.70% | $0.1700 (+32.00%) |
Apr 15, 2026 27w ago | 8-K | $0.2800 $0.2500 | ▼ −10.71% | ▼ −16.76% | $0.1700 (−39.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers